sPARK.
Active

RNA Neoantigen Vaccine

Personalized mRNA vaccines targeting tumor neoantigens

Personalized RNA neoantigen vaccine program priming durable, long-lived T-cell responses in pancreatic cancer.

NeoantigenVaccineImmunotherapyPDAC

Overview

Personalized RNA neoantigen vaccines are designed against each patient’s tumor-specific mutations to direct T cells against cancer-defining epitopes.

Findings

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer (Nature, 2023) and prime long-lived CD8+ T cells (Nature, 2025), supporting the durability of vaccine-induced immune responses.

Research Programs

ProgramNeoantigens & Biologics

Publications

Nature 618(7963), 144–150 · 2023Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancerNature 639(8056), 1042–1051 · 2025RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer